While the impact of unanticipated tariff policy changes in early April was market-wide, the recovery has been less even. Despite a major rebound following the sell-off, some firms have been sluggish to reclaim lost ground. This has given faster-moving stocks an opportunity to stand out as fresh momentum plays in the meantime. Investors looking for high-momentum stocks following this period of turbulence should consider whether the factors are short-term or indicative of potentially longer-term trajectories. ...

Certara, Inc. CERT on Monday announced expected revenue and bookings for the first quarter.Here’s what the company expects:Revenue of $106 million, compared to $96.7 million in the first quarter of 2024, representing growth of 10% versus consensus of $104.42 million.Software revenue of $46.4 million, up 18%, and services revenue of $59.6 million, up 4%.Interim Q1 bookings of $118 million, up 12%, include software bookings of $40.6 million and services bookings of $77.4 million.Preliminary revenue and bookin ...

New offering provides strategic guidance and AI-enabled biosimulation to navigate FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety StudiesRADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of its Non-Animal Navigator™ solution designed to help biopharmaceutical companies lead the transition ignited by the FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety Studies. The Roadmap m ...

Revenue Projections - Preliminary revenue for Q1 2025 is expected to be $106.0 million, a 10% increase from $96.7 million in Q1 2024[5] - Software revenue for Q1 2025 is projected at $46.4 million, reflecting an 18% growth compared to $39.3 million in Q1 2024[5] - Services revenue for Q1 2025 is anticipated to be $59.6 million, representing a 4% increase from $57.3 million in Q1 2024[5] - Full-year 2025 revenue guidance is reiterated to be between $415 million and $425 million[12] Bookings and Growth - Bookings for Q1 2025 are expected to reach $118.0 million, a 12% growth from $105.8 million in Q1 2024[5] - Adjusted EBITDA for Q1 2025 is projected to be in the range of $33-$35 million, indicating a growth of 13-20% from $29.1 million in Q1 2024[5] - Full-year adjusted EBITDA margin is expected to be in the range of 30-32%[12] Earnings and Shareholder Returns - Full-year adjusted diluted earnings per share is anticipated to be between $0.42 and $0.46[12] - The company has authorized a stock repurchase program of up to $100 million[2] Shareholder Agreements - Arsenal Capital Partners has agreed to a one-year lock-up on shares acquired in a December 2022 transaction[3]

Reiterates Full-Year 2025 Guidance Arsenal Capital Partners agrees to a one-year lock-up RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced expected revenue and bookings for the first quarter of 2025 based upon a preliminary review of first quarter results. Additionally, the company announced that its Board of Directors has authorized a stock repurchase program under which the company may repurchase up to $100 mill ...

Reiterates Full-Year 2025 Guidance Arsenal Capital Partners agrees to a one-year lock-up RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced expected revenue and bookings for the first quarter of 2025 based upon a preliminary review of first quarter results. Additionally, the company announced that its Board of Directors has authorized a stock repurchase program under which the company may repurchase up to $100 mil ...

Chris Lau is an individual investor and economist with 30 years of experience covering life science, technology, and dividend-growth income stocks. He has degrees in Microbiology and Economics. Chris runs the investing group DIY Value Investing where he shares his top stock picks of undervalued stocks with catalysts for upside, dividend-income recommendations with quant and payment calendar tracking, high upside plays, and research requests to help you become a better do-it-yourself investor. Learn more.Top ...

Certara, Inc. (CERT) shares soared 8% in the last trading session to close at $10.51. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 11.6% loss over the past four weeks.Earlier this month, the company released a new version of the Simcyp Simulator for physiologically-based pharmacokinetic (PBPK) modeling, which forecasts the behavior of drugs in different body tissues. Per management, the latest version cements Certara’s positio ...

Updates strengthen Certara's position as a leader of PBPK modeling in drug development to advance regulatory decision-making RADNOR, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has released a new version of the Simcyp™ Simulator for physiologically- based pharmacokinetic (PBPK) modeling. Simcyp PBPK models describe and predict the behavior of drugs in different body tissues. The latest version includes numerous advancements to fur ...

"We're advancing the Simcyp Simulator to address the evolving needs of our pharmaceutical collaborators and regulators," Rob Aspbury, President, Certara Predictive Technologies said. "Simcyp Version 24 supports the growing adoption of PBPK in drug development and regulatory decision-making, as well as the broader applications of PBPK from discovery through clinical development." RADNOR, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, h ...